Stock listing
NASDAQ:CELU Celularity Inc. Stock
Home listing (NASDAQ) of Celularity Inc.
Follow Celularity Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CELU
$0.463 USD -0.020 (-4.2%)
Close on Nov 20, 2026
- Day range
- $0.420 – $0.500 USDNov 20, 2026
- Volume
- 295,913 sharesNov 20, 2026
- Market cap
- $15.02M USDAt the close on Nov 20, 2026 · price × 32.45M shares outstanding
- 52-week range
- $0.420 – $2.550 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.85M USDMedian day 149,414 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CELU · Home | $0.463 USD | -0.020 (-4.2%) | 295,913 | $0.500 | $0.500 | $0.420 | $0.483 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CELU · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.463 | -0.020 | -4.2% | $0.500 | $0.500 | $0.420 | 295,913 | |
| $0.483 | -0.088 | -15.4% | $0.580 | $0.720 | $0.465 | 653,738 | |
| $0.571 | -0.048 | -7.8% | $0.640 | $0.730 | $0.550 | 229,541 | |
| $0.619 | -0.011 | -1.7% | $0.630 | $0.630 | $0.597 | 106,835 | |
| $0.630 | -0.055 | -8.0% | $0.700 | $0.710 | $0.612 | 138,784 | |
| $0.685 | -0.066 | -8.8% | $0.767 | $0.800 | $0.650 | 122,107 | |
| $0.751 | +0.040 | +5.6% | $0.716 | $0.775 | $0.701 | 66,301 | |
| $0.711 | -0.049 | -6.4% | $0.750 | $0.763 | $0.705 | 102,764 | |
| $0.760 | 0.000 | -0.1% | $0.751 | $0.800 | $0.720 | 151,279 | |
| $0.760 | +0.035 | +4.8% | $0.732 | $0.769 | $0.724 | 60,564 | |
| $0.725 | -0.084 | -10.3% | $0.800 | $0.820 | $0.721 | 167,156 | |
| $0.809 | -0.008 | -1.0% | $0.859 | $0.870 | $0.799 | 72,008 | |
| $0.817 | +0.015 | +1.8% | $0.808 | $0.900 | $0.799 | 69,341 | |
| $0.803 | +0.002 | +0.3% | $0.800 | $0.860 | $0.790 | 98,822 | |
| $0.800 | -0.049 | -5.8% | $0.820 | $0.869 | $0.800 | 181,847 | |
| $0.849 | -0.091 | -9.7% | $0.980 | $0.980 | $0.834 | 496,839 | |
| $0.940 | +0.150 | +19.0% | $0.821 | $1.040 | $0.782 | 350,936 | |
| $0.790 | +0.040 | +5.4% | $0.800 | $0.868 | $0.780 | 219,290 | |
| $0.750 | -0.228 | -23.3% | $0.964 | $1.000 | $0.660 | 629,002 | |
| $0.978 | -0.072 | -6.9% | $1.060 | $1.142 | $0.911 | 145,347 | |
| $1.050 | +0.030 | +2.9% | $1.070 | $1.080 | $1.010 | 144,726 | |
| $1.020 | -0.240 | -19.0% | $1.310 | $1.310 | $1.020 | 204,708 | |
| $1.260 | +0.100 | +8.6% | $1.160 | $1.300 | $1.160 | 60,140 | |
| $1.160 | -0.090 | -7.2% | $1.290 | $1.290 | $1.121 | 87,785 | |
| $1.250 | -0.080 | -6.0% | $1.330 | $1.330 | $1.220 | 64,070 | |
| $1.330 | +0.020 | +1.5% | $1.280 | $1.350 | $1.270 | 30,651 | |
| $1.310 | -0.110 | -7.7% | $1.390 | $1.410 | $1.280 | 80,188 | |
| $1.420 | -0.050 | -3.4% | $1.450 | $1.550 | $1.400 | 50,371 | |
| $1.470 | -0.090 | -5.8% | $1.560 | $1.570 | $1.461 | 43,731 | |
| $1.560 | +0.100 | +6.8% | $1.460 | $1.570 | $1.451 | 53,197 | |
| $1.460 | -0.010 | -0.7% | $1.460 | $1.500 | $1.430 | 103,708 | |
| $1.470 | -0.110 | -7.0% | $1.530 | $1.570 | $1.470 | 68,941 | |
| $1.580 | -0.130 | -7.6% | $1.700 | $1.769 | $1.540 | 260,947 | |
| $1.710 | +0.110 | +6.9% | $1.600 | $1.800 | $1.570 | 282,127 | |
| $1.600 | +0.220 | +15.9% | $1.370 | $1.635 | $1.360 | 221,844 | |
| $1.380 | +0.030 | +2.2% | $1.340 | $1.380 | $1.302 | 142,148 | |
| $1.350 | -0.020 | -1.5% | $1.370 | $1.370 | $1.280 | 55,429 | |
| $1.370 | -0.030 | -2.1% | $1.380 | $1.400 | $1.334 | 39,646 | |
| $1.400 | +0.020 | +1.4% | $1.400 | $1.460 | $1.350 | 113,620 | |
| $1.380 | +0.060 | +4.5% | $1.330 | $1.410 | $1.320 | 166,069 | |
| $1.320 | +0.170 | +14.8% | $1.170 | $1.350 | $1.170 | 454,723 | |
| $1.150 | -0.030 | -2.5% | $1.170 | $1.180 | $1.130 | 77,117 | |
| $1.180 | -0.060 | -4.8% | $1.220 | $1.260 | $1.160 | 154,730 | |
| $1.240 | -0.070 | -5.3% | $1.270 | $1.330 | $1.240 | 214,037 | |
| $1.310 | +0.040 | +3.1% | $1.280 | $1.350 | $1.220 | 188,400 | |
| $1.270 | -0.020 | -1.6% | $1.290 | $1.380 | $1.270 | 77,758 | |
| $1.290 | +0.050 | +4.0% | $1.260 | $1.389 | $1.210 | 181,095 | |
| $1.240 | -0.160 | -11.4% | $1.330 | $1.400 | $1.240 | 149,414 | |
| $1.400 | -0.010 | -0.7% | $1.320 | $1.430 | $1.310 | 206,968 | |
| $1.410 | -0.025 | -1.7% | $1.450 | $1.450 | $1.351 | 97,105 | |
| $1.435 | -0.005 | -0.3% | $1.405 | $1.480 | $1.385 | 158,545 | |
| $1.440 | -0.100 | -6.5% | $1.550 | $1.550 | $1.430 | 148,745 | |
| $1.540 | -0.140 | -8.3% | $1.700 | $1.734 | $1.520 | 249,671 | |
| $1.680 | -0.150 | -8.2% | $1.830 | $1.830 | $1.618 | 351,362 | |
| $1.830 | -0.030 | -1.6% | $1.850 | $1.894 | $1.780 | 363,695 | |
| $1.860 | -0.020 | -1.1% | $1.880 | $1.960 | $1.690 | 654,741 | |
| $1.880 | +0.030 | +1.6% | $1.860 | $2.070 | $1.710 | 1,622,079 | |
| $1.850 | +0.270 | +17.1% | $1.420 | $1.964 | $1.380 | 3,422,193 | |
| $1.580 | -0.520 | -24.8% | $2.145 | $2.200 | $1.480 | 15,087,260 | |
| $2.100 | +1.220 | +138.5% | $1.110 | $2.550 | $0.926 | 221,052,891 | |
| $0.880 | +0.080 | +9.9% | $0.806 | $0.976 | $0.780 | 177,414 | |
| $0.801 | +0.026 | +3.4% | $0.751 | $1.110 | $0.751 | 1,184,841 | |
| $0.775 | -0.025 | -3.2% | $0.775 | $0.860 | $0.749 | 37,347 | |
| $0.800 | +0.033 | +4.3% | $0.770 | $0.850 | $0.731 | 26,346 | |
| $0.767 | -0.011 | -1.4% | $0.701 | $0.820 | $0.701 | 46,739 |
Splits
1 split · NASDAQ:CELU · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:CELU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 29, 2026
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
Latest news
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
Oct 29, 2026
Closed $0.849 (-9.7%) on Oct 29, 2026
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
Oct 22, 2026
Closed $1.05 (+2.9%) on Oct 22, 2026
Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
Oct 20, 2026
Closed $1.02 (-19.0%) on Oct 21, 2026
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Sep 30, 2026
Closed $1.35 (-1.5%) on Sep 30, 2026
Celularity Announces Naveen Jain to Join Board of Directors
Sep 29, 2026
Closed $1.37 (-2.1%) on Sep 29, 2026
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
Sep 24, 2026
Closed $1.32 (+14.8%) on Sep 24, 2026
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
Aug 27, 2026
Closed $2.10 (+138.5%) on Aug 27, 2026
Celularity Provides Update Regarding Nasdaq Listing Compliance
Aug 25, 2026
Closed $0.88 (+9.9%) on Aug 26, 2026
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Jun 4, 2026
Closed $0.995 (-2.5%) on Jun 4, 2026
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Jun 3, 2026
Closed $1.02 (-3.8%) on Jun 3, 2026
Celularity Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 121 in all · newest Oct 29, 2026 · oldest 2021
- Decks
- 14 decks · latest February 2025
Where Celularity Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CELU · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CELU | BOATS | United States | USD |
Valuation
EV/sales 2.7× against a median of 4.8×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $50.46M USD
- P/E
- Loss
- EV/sales
- 2.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- −5.6%
- Operating margin
- −216.1%
- Net margin
- −117.3%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Context Therapeutics Inc. · NASDAQ:CNTX | US$14.70M | −US$19.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.99 |
| NewcelX Ltd. · NASDAQ:NCEL | US$14.67M | US$14.35M | n/a | n/a | n/a | 2.4× | n/a | 0.1× | 0.89 |
| Hepion Pharmaceuticals, Inc. · OTC:HEPA | US$14.63M | US$10.37M | n/a | n/a | n/a | n/a | n/a | n/a | -1.02 |
| Vectorite Biomedical, Inc. · TPEX:4170 | US$14.21M | US$9.16M | 4.9× | 4.9× | n/a | 0.9× | 156.6% | 0.0× | n/a |
| Estrella Immunopharma, Inc. · NASDAQ:ESLA | US$14.11M | US$14.01M | n/a | n/a | n/a | n/a | n/a | n/a | 1.31 |
| Median of the others | US$15.23M | US$9.77M | 4.9× | 4.8× | −0.1× | 0.7× | −265.0% | 0.0× | 0.89 |
Team and board
Officers
| Officer | Role |
|---|---|
| Robert J. Hariri | Chairperson, Founder, and CEO |
| Carlos Ramirez | SVP, Investor Relations |
| Rick Gonzalez | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Robert J. Hariri | Chairperson, Founder, and CEO |
| Diane Parks | Director |
| Geoffrey Shiu Fei Ling | Director |
| Naveen Jain | Director |
| Peter Diamandis | Director |
| Philip A. Barach | Director |
| Vincent LeVien | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 20, 2026 | |
| Q2 2026 | Sep 29, 2026 | −3.6% |
| Q1 2026 | May 29, 2026 | +8.0% |
| Q3 2025 | Nov 14, 2025 | −4.4% |
| Q2 2025 | Aug 18, 2025 · After close | −13.0% |
| Q1 2025 | May 8, 2025 | 0.0% |
| Q4 2024 | Feb 26, 2025 | −15.9% |
| Q3 2024 | Dec 31, 2024 · After close | +5.8% |
| Q2 2024 | Aug 7, 2024 | −4.2% |
| Q1 2024 | May 14, 2024 | +14.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Jan 2, 2024 · After close | +0.5% |
| Q3 2023 | Dec 5, 2023 · Before open | −3.4% |
| Q2 2023 | Aug 14, 2023 · After close | −0.1% |
| Q1 2023 | May 22, 2023 · After close | −2.3% |
| Q4 2022 | Mar 31, 2023 · After close | +19.4% |
| Q3 2022 | Nov 10, 2022 · After close | −4.7% |
| Q2 2022 | Aug 9, 2022 · After close | +3.8% |
| Q1 2022 | May 16, 2022 · After close | +17.8% |
| Q4 2021 | Mar 31, 2022 · After close | +1.9% |
| Q3 2021 | Nov 12, 2021 · After close | −4.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2025) | Investor deck | 28 slides | February 2025 |
| Investor Presentation (September 2024) | Investor deck | 22 slides | September 2024 |
| Investor Day (May 2024) | Investor day | 59 slides | May 21, 2024 |
| Investor Presentation (June 2023) | Investor deck | 14 slides | June 2023 |
| Investor Presentation (June 2022) | Investor deck | 34 slides | June 2022 |
| Investor Presentation (June 2022) | Investor deck | 33 slides | June 2022 |
| Investor Presentation (May 2022) | Investor deck | 28 slides | May 2022 |
| Corporate Update (December 2021) | Corporate update | 16 slides | Dec 17, 2021 |
| Investor Presentation (October 2021) | Investor deck | 44 slides | October 2021 |
| Investor Presentation (October 2021) | Investor deck | 44 slides | October 2021 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2021) | Investor deck | 51 slides | July 2021 |
| GX Acquisition — SPAC Merger (April 2021) | SPAC merger | 51 slides | Apr 28, 2021 |
| GX Acquisition — SPAC Merger (February 2021) | SPAC merger | 55 slides | Feb 11, 2021 |
| SPAC Merger (January 2021) | SPAC merger | 54 slides | Jan 8, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of senior secured convertible notes and warrants Tranche closed: US$10M raised · Warrants at US$1.5 for 60 months · Odeon Capital Group LLC Dealers: Odeon Capital Group LLC (lead) Buyers: Philip A. Barach Use of proceeds: Support commercial execution and manufacturing expansion | Sep 24, 2026 |
| Senior secured term loan with warrants Announced: US$7M · Warrants at US$2 Buyers: Philip A. Barach Use of proceeds: Support strategic priorities around longevity and preservation of human performance | Dec 18, 2025 |
| Secured convertible notes Announced: up to US$5M · Warrants at US$2 Buyers: Philip A. Barach Use of proceeds: Support strategic priorities around longevity and preservation of human performance | Dec 18, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as GX Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on May 20, 2019.
- Price
- US$10.00 a unit
- Units offered
- 25,000,000 units
- Offering size
- US$250 million
- Underwriters' option
- Up to 3,750,000 more units
- Listing
- GXGXU on the Nasdaq Capital Market
- Underwriter
- Cantor
- Units delivered
- On or about May 23, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 5, 2018 |
| Filed publicly | Apr 26, 2019 |
| Amended once | May 13, 2019 |
| Shares registered with an exchange | May 17, 2019 |
| Declared effective by the SEC | May 20, 2019 |
| Final prospectus, with the price | May 21, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 21, 2019 |
| CERT · Exchange's certificate of listing | May 21, 2019 |
| EFFECT · Notice that a registration is effective | May 20, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | May 17, 2019 |
| CORRESP · Letter to the SEC | May 16, 2019 |
| CORRESP · Letter to the SEC | May 16, 2019 |
| S-1/A · Registration statement, amended | May 13, 2019 |
| CORRESP · Letter to the SEC | Apr 26, 2019 |
| S-1 · Registration statement | Apr 26, 2019 |
| UPLOAD · Letter from the SEC | Apr 10, 2019 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Mar 28, 2019 |
| DRS/A · Draft registration statement, amended | Mar 28, 2019 |
| UPLOAD · Letter from the SEC | Nov 29, 2018 |
| DRS · Draft registration statement | Nov 5, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed May 21, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.6M | 54.2M | 22.8M | 18.0M | 21.3M | 14.3M | 21.1M | 17.6M |
| Cost of revenue | 20.1M | 15.0M | 16.0M | 19.7M | 9.65M | 4.93M | 6.32M | 6.55M |
| Gross profit | 6.48M | 39.2M | 6.75M | -1.69M | 11.7M | 9.35M | 14.8M | 11.0M |
| Research and development | 15.0M | 17.4M | 30.5M | 78.4M | 88.4M | 52.7M | 46.1M | 29.1M |
| Selling, general and administrative | 51.3M | 58.6M | 50.6M | 66.0M | 71.3M | 31.3M | 40.6M | |
| Operating income | -61.3M | -38.4M | -192.3M | -25.6M | -109.1M | -151.9M | -1.68M | -1.10K |
| Depreciation and amortization | 7.29M | 7.92M | 9.32M | 9.44M | 8.82M | 8.17M | 6.19M | 4.79M |
| EBITDA | -54.0M | -30.4M | -183.0M | -16.2M | -100.2M | -143.8M | 4.50M | 4.79M |
| Interest expense | 6.75M | 6.26M | 3.02M | 3.17M | 3.17M | 2.35M | 3.75M | 0 |
| Income before tax | -91.7M | -57.9M | -196.3M | 14.2M | -100.1M | -212.9M | 6.55M | -1.10K |
| Income tax | 3.00K | 10.0K | 10.0K | 13.0K | 20.0K | -4.70M | 668.2K | 21.3M |
| Net income | -91.7M | -57.9M | -196.3M | 14.2M | -100.1M | -208.2M | 5.88M | -1.10K |
| Earnings per share, basic | -3.59 | -2.64 | -11.02 | 1.01 | -1.49 | -11.31 | 0.10 | -0.00 |
| Earnings per share, diluted | -3.59 | -2.64 | -11.02 | 0.95 | -1.49 | -11.31 | 0.10 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.17M | 738.0K | 227.0K | 14.0M | 37.2M | 54.3M | 917.0K | 24.7K |
| Receivables | 4.65M | 13.6M | 10.0M | 6.97M | 5.23M | 6.55M | 3.08M | 3.92M |
| Inventory | 571.0K | 5.41M | 5.75M | 5.31M | 9.55M | 9.55M | 3.23M | 3.54M |
| Current assets | 12.3M | 20.6M | 19.8M | 33.5M | 59.1M | 72.2M | 1.01M | 24.7K |
| Property, plant and equipment | 55.8M | 61.6M | 67.8M | 75.7M | 90.6M | 90.1M | 66.4M | 4.01M |
| Goodwill | 7.35M | 7.35M | 7.35M | 119.7M | 123.3M | 123.3M | 127.1M | 130.6M |
| Total assets | 107.3M | 132.7M | 143.9M | 401.1M | 414.1M | 431.0M | 291.6M | 24.7K |
| Accounts payable | 26.4M | 23.3M | 14.1M | 5.81M | 9.32M | 5.39M | 18.9K | 5.27M |
| Current liabilities | 80.8M | 53.7M | 67.3M | 62.1M | 26.2M | 26.7M | 229.1K | 150.6K |
| Long-term debt | 33.8M | 35.9M | ||||||
| Total debt | 40.9M | 68.8M | 65.6M | 31.1M | 30.6M | 28.1M | 150.0K | |
| Total liabilities | 145.4M | 123.8M | 102.9M | 202.2M | 314.7M | 412.3M | 28.2M | 150.6K |
| Shareholders' equity | -38.1M | 8.84M | 41.0M | 198.9M | 99.4M | -531.4M | -327.4M | -125.8K |
| Shares outstanding | 28.8M | 22.5M | 19.4M | 14.9M | 124.3M | 18.5M | 3.17M | 3.59M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13.3M | -6.40M | -38.7M | -137.9M | -110.1M | -63.2M | -1.10M | -543 |
| Capital spending | 0 | -161.0K | -1.05M | -5.24M | -6.20M | -27.8M | -3 | -1.92M |
| Free cash flow | -13.3M | -6.56M | -39.7M | -143.1M | -116.3M | -91.0M | -1.10M | -1.92M |
| Cash from investing | 514.0K | -4.05M | -5.24M | -5.90M | -12.8M | -286.8M | -31.2M | |
| Cash from financing | 18.6M | 6.70M | 24.1M | 119.8M | 98.6M | 102.0M | 288.8M | 25.3K |
| Dividends paid | -5.90M | 0 | -39.1M | |||||
| Share buybacks | -132.0K | 0 | -256.0K | 6.49M | ||||
| Change in cash | 5.39M | 814.0K | -18.6M | -23.3M | -17.4M | 26.0M | 892.3K | -31.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| NT 10-Q · Late filing notice | Nov 16, 2026 | Explanation request | SEC |
| ARS · Annual report to shareholders | Nov 10, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Nov 10, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 28, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Oct 20, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Oct 20, 2026 | Annual report | SEC |
| 8-K · Current report | Sep 29, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Sep 29, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 28, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2026 | Explanation request | SEC |
| 8-K · Current report | Aug 7, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 29, 2026 | Current report | SEC |
| 25-NSE | Jul 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 30, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 25, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 12, 2026 | Current report | SEC |
| 8-K · Current report | Jun 3, 2026 | Management or board change | SEC |
| 8-K · Current report | May 28, 2026 | Material contract | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| 10-K · Annual report | Apr 30, 2026 | Annual report | SEC |
| 3 · Initial statement of ownership | Apr 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 24, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 22, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Material contract | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 3, 2026 | Big-stake notice | SEC |
| NT 10-K · Late filing notice | Mar 31, 2026 | Explanation request | SEC |
| 8-K · Current report | Mar 10, 2026 | Material contract | SEC |
| 8-K · Current report | Mar 5, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 21, 2026 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Jan 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 8, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 5, 2026 | Other filings | SEC |
| S-1 · Registration statement | Dec 31, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 30, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 30, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 23, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Dec 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| S-1 · Registration statement | Dec 19, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 19, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Nov 7, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Nov 7, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Nov 7, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 7, 2025 | Meeting notice | SEC |
| D | Nov 3, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 28, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 29, 2025 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 29, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 27, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 18, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 12, 2025 | Material contract | SEC |
| D | Aug 5, 2025 | Other filings | SEC |
| D | Aug 5, 2025 | Other filings | SEC |
| D | Aug 5, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 1, 2025 | Material contract | SEC |
| 8-K · Current report | Jul 30, 2025 | Material contract | SEC |
| 8-K/A · Current report, amended | Jul 29, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 22, 2025 | Material contract | SEC |
| 3 · Initial statement of ownership | Jul 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 6, 2025 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Jun 4, 2025 | Insider trade | SEC |
| 10-K/A · Annual report, amended | May 21, 2025 | Annual report | SEC |
| 8-K · Current report | May 20, 2025 | Material contract | SEC |
| 8-K · Current report | May 16, 2025 | Management or board change | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| 10-K · Annual report | May 8, 2025 | Annual report | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Mar 21, 2025 | Material contract | SEC |
| RW · Request to withdraw a registration | Mar 10, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Feb 13, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 13, 2025 | Other filings | SEC |
| FWP · Free writing prospectus | Feb 13, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Feb 13, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jan 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 28, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 27, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 3, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 20, 2024 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Dec 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 19, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Dec 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Dec 2, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 27, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 19, 2024 | Meeting notice | SEC |
| NT 10-Q · Late filing notice | Nov 15, 2024 | Explanation request | SEC |
| 8-K · Current report | Nov 8, 2024 | Current report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 25, 2024 | Results | SEC |
| 8-K · Current report | Oct 21, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Oct 16, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 16, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 13, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 23, 2024 | Current report | SEC |
| NT 10-Q · Late filing notice | Aug 16, 2024 | Explanation request | SEC |
| 8-K · Current report | Aug 5, 2024 | Management or board change | SEC |
| 10-K · Annual report | Jul 30, 2024 | Annual report | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 8-K · Current report | May 21, 2024 | Results | SEC |
| NT 10-Q · Late filing notice | May 15, 2024 | Explanation request | SEC |
| 8-K · Current report | Apr 22, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| NT 10-K · Late filing notice | Apr 1, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 15, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 15, 2024 | Material contract | SEC |
| 8-K · Current report | Feb 26, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Feb 22, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2024 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Feb 2, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 23, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 17, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 17, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | Jan 2, 2024 | Quarterly report | SEC |
| 8-K · Current report | Dec 29, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 24, 2023 | Current report | SEC |
This page holds 200 of 564 filings. Open Filings
Cap table
Built by 6ix from Celularity Inc.’s releases · as of Sep 30, 2026
- Common shares
- 32,449,891
- Fully diluted
- 32,449,891
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 32,449,891 | Sep 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.50 · expire about Sep 2031 |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 32,449,891 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robin L. Smith Other companies: Matinas BioPharma Holdings, Inc. (Director · Feb 13, 2025 – Nov 4, 2026 · Past); Cycurion, Inc. (Director · Jan 11, 2022 – Jan 11, 2022 · Past); ServiceSource International Inc (Director · Feb 27, 2020 – May 20, 2020 · Past); Sorrento Therapeutics, Inc. (Director · Dec 16, 2019 – Sep 3, 2021 · Past); Rockwell Medical, Inc. (Director · Jun 6, 2019 – Jun 6, 2019 · Past); Emmaus Life Sciences, Inc. (Director · May 8, 2019 – May 8, 2019 · Past) | Director · Jul 16, 2021 – Jun 14, 2023 · Past |
| Andrew C Von Eschenbach Other companies: Bausch + Lomb Corporation (Director · Since at least May 5, 2022); TriSalus Life Sciences, Inc. (Director · Aug 10, 2023 – Aug 13, 2024 · Past); Radius Health, Inc. (Director · Aug 15, 2022 – Aug 15, 2022 · Past) | Director · Jul 13, 2022 – Jun 14, 2023 · Past |
| Dean Kehler Other companies: NioCorp Developments Ltd. (Director · Since at least Mar 17, 2023); BCP Investment Corporation (Independent Director · Since at least Feb 29, 2012); El Pollo Loco Holdings, Inc. (Director · Jul 24, 2014 – Aug 31, 2022 · Past) | Director · May 20, 2019 – Dec 19, 2024 · Past |
| Diane Parks Other companies: Kura Oncology, Inc. (Director · Since at least Oct 14, 2019); Soligenix, Inc. (Board Director · Since at least Jul 8, 2019); CTi Biopharma Corp (Director · Aug 24, 2021 – Jun 26, 2023 · Past) | Director · Since at least Jun 2, 2022 |
| John Sculley Other companies: Zeta Global Holdings Corp. (Director · Jun 9, 2021 – Jun 9, 2025 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Feb 27, 2019 · Past); Decoy Therapeutics Inc. (Director · Jan 28, 2015 – Jun 8, 2016 · Past) | Director · Jul 16, 2021 – Jun 14, 2023 · Past |
| Marc Mazur Other companies: Soren Acquisition Corp. (Independent Director · Since at least Jan 6, 2026); SuRo Capital Corp. (Director · Since at least Jul 2, 2020); Fibrocell Science Inc (Director · Jun 22, 2016 – Dec 13, 2019 · Past) | Director · May 20, 2019 – Jun 14, 2023 · Past |
| Peter Diamandis Other companies: Vaxxinity, Inc. (Director · Nov 10, 2021 – Jun 20, 2023 · Past); DPCM Capital Inc (Director · Oct 20, 2020 – Aug 5, 2022 · Past); CuriosityStream Inc. (Director · Nov 19, 2019 – Nov 19, 2019 · Past) | Director · Since at least Jul 16, 2021 |
| Michael Maselli Other companies: NioCorp Developments Ltd. (Director · Since at least Mar 17, 2023); El Pollo Loco Holdings, Inc. (Director · Jul 24, 2014 – May 9, 2023 · Past) | Vice President of Acquisitions · May 20, 2019 – May 20, 2019 · Past |
| Adrian Kilcoyne Other companies: Humanigen Inc (Chief Medical Officer · Apr 21, 2021 – Jul 27, 2022 · Past) | Chief Medical Officer · Sep 29, 2022 – Feb 16, 2024 · Past |
| Geoffrey M D Ling Other companies: Gyre Therapeutics, Inc. (Director · Jan 15, 2020 – Jan 7, 2022 · Past) | Director · Since at least Aug 31, 2023 |
All 26 people
| Person | Seat |
|---|---|
| Robert J. Hariri Other companies: CryoPort, Inc. (Chairman of the Scientific and Technology Committee · Since at least May 28, 2025) | Chairperson, Founder, and CEO · Since at least Apr 13, 2025 |
| Andrea J Kellett | Chief Financial Officer · May 20, 2019 – May 20, 2019 · Past |
| Anne Jones | Chief Business Officer · Jul 16, 2021 – Jul 13, 2022 · Past |
| Bradley Glover | See Remarks · Jul 16, 2021 – Apr 13, 2023 · Past |
| Carlos Ramirez | SVP, Investor Relations · Since at least Jun 3, 2026 |
| David C Beers | Chief Financial Officer · Apr 13, 2025 – Apr 13, 2025 · Past |
| Geoffrey Shiu Fei Ling | Director · Since at least Nov 5, 2026 |
| Hillel Weinberger | Director · May 20, 2019 – May 20, 2019 · Past |
| John R Haines | Senior Exec Vice President · Since at least Jul 16, 2021 |
| Joseph DosSantos | Interim CFO · Since at least Jun 10, 2025 |
| Kyle Fletcher | See Remarks · Jul 13, 2022 – Apr 13, 2024 · Past |
| Naveen Jain | Director · Since at least Sep 29, 2026 |
| Philip A. Barach | Director · Since at least Sep 24, 2026 |
| Rick Gonzalez | Chief Commercial Officer · Since at least Jun 3, 2026 |
| Stephen Brigido | Pres., Functional Regeneration · Since at least Jul 16, 2021 |
| Vincent LeVien | Director · Since at least Jun 5, 2025 |
Log in to ask 6ix AI your own questions about Celularity Inc.